tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Takaya S et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. 1992 Transplantation pmid:1371195
Francavilla A et al. Inhibition of liver, kidney, and intestine regeneration by rapamycin. 1992 Transplantation pmid:1371198
Matsukawa W et al. Effects of a new immunosuppressive agent, FK506, in rats with active Heymann nephritis. 1992 J. Lab. Clin. Med. pmid:1371298
Sampson BA and Gotschlich EC Neisseria meningitidis encodes an FK506-inhibitable rotamase. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1371354
Andersson J et al. Effects of FK506 and cyclosporin A on cytokine production studied in vitro at a single-cell level. 1992 Immunology pmid:1371491
Strasser S et al. Effect of FK506 on insulin secretion in normal dogs. 1992 Metab. Clin. Exp. pmid:1371575
Andersson J et al. FK 506 and cyclosporine inhibit antigen- or mitogen-induced monokine and lymphokine production in vitro. 1992 Transplant. Proc. pmid:1371621
Matsuura T et al. Blockade of interleukin-2 production from cloned T cells by cyclosporine and FK 506 assessed by proliferation assays in vitro. 1992 Transplant. Proc. pmid:1371623
Okamura N et al. Enhanced liver regeneration by FK 506 can be blocked by interleukin-1 alpha and interleukin-2. 1992 Transplant. Proc. pmid:1371624
Sakr M et al. Effect of renal ischemia on plasma levels of FK 506 in rats. 1992 Transplant. Proc. pmid:1371625
Stangl MJ et al. The use of FK506 and RS61443 for reversal of small-bowel rejection. 1992 Transpl. Int. pmid:14621800
Kusne S et al. Infections during a randomized trial comparing cyclosporine to FK 506 immunosuppression in liver transplantation. 1992 Transplant. Proc. pmid:1371626
Wijnen RM et al. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. 1992 Transpl. Int. pmid:14621844
Lee C et al. FK-506 binding protein from Tolypocladium inflatum: resistance of FKBP/FK-506 complex against proteolysis. 1992 Biochem. Biophys. Res. Commun. pmid:1371677
Jiang H et al. Control of humoral and cellular immunity-mediated accelerated heart allograft rejection in sensitized rats by low dose FK 506 and splenectomy. 1992 Transpl. Int. pmid:14621859
Edkins RD et al. Comparison of cyclosporine and FK506 effects on glutathione levels in rat cochlea, brain, liver and kidney. 1992 Biochem. Pharmacol. pmid:1371687
Kobayashi N et al. Abdominal organ cluster transplantation in pigs and FK506. 1992 Transpl. Int. pmid:14621861
Metcalfe S et al. FK506 and rapamycin: differential sensitivity of human, baboon, cynomolgus monkey, dog and pig lymphocytes. 1992 Transpl. Int. pmid:14621863
Japanese study of kidney transplantation: 1. Results of early phase II study. 1992 Transpl. Int. pmid:14621866
Japanese study of FK 506 on kidney transplantation: 2. Follow-up study of FK 506-treated patients. 1992 Transpl. Int. pmid:14621874
Walpoth B et al. Prevention of cardiac allograft rejection by FK506 and rapamycin: assessment by histology and nuclear magnetic resonance. 1992 Transpl. Int. pmid:14621877
Asako H et al. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. 1992 Transplantation pmid:1384191
Kawano K et al. FK 506 ameliorates normothermic liver ischemia in rats by suppressing production of tumor necrosis factor. 1992 Transpl. Int. pmid:14621904
Fruman DA et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1373887
Lake JR et al. Maintenance immunosuppression after liver transplantation. 1992 Semin. Liver Dis. pmid:1373916
Taormina D et al. Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. 1992 Am J Hosp Pharm pmid:1373936
Ochiai T [Advances in the fundamentals and therapeutic use of immunosuppressive agents]. 1992 Arerugi pmid:1374229
Yamada K et al. New morphological changes induced by FK506 in a short period in the rat kidney and the effect of superoxide dismutase and OKY-046 on THEM: the relationship of FK506 nephrotoxicity to lipid peroxidation and change in production of thromboxane A2 in the kidney. 1992 Transpl. Int. pmid:14621878
Hung DT and Schreiber SL cDNA cloning of a human 25 kDa FK506 and rapamycin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1374240
Jayaraman T et al. FK506 binding protein associated with the calcium release channel (ryanodine receptor). 1992 J. Biol. Chem. pmid:1374404
Höllsberg P et al. Characterization of HTLV-I in vivo infected T cell clones. IL-2-independent growth of nontransformed T cells. 1992 J. Immunol. pmid:1374452
Schreiber SL and Crabtree GR The mechanism of action of cyclosporin A and FK506. 1992 Immunol. Today pmid:1374612
Demetris AJ et al. Conversion of liver allograft recipients from cyclosporine to FK506 immunosuppressive therapy--a clinicopathologic study of 96 patients. 1992 Transplantation pmid:1374944
Bundick RV et al. FK506 as an agonist to induce inhibition of interleukin 2 production. 1992 Transplantation pmid:1374947
Sakr M et al. The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. 1992 Transplantation pmid:1374948
Lepre CA et al. Solution structure of FK506 bound to FKBP-12. 1992 FEBS Lett. pmid:1375171
Ruff VA et al. FKBP-12 is not an inhibitor of protein kinase C. 1992 Immunol. Invest. pmid:1375189
de Paulis A et al. Anti-inflammatory effect of FK-506 on human skin mast cells. 1992 J. Invest. Dermatol. pmid:1281861
Hisanaga M et al. Successful combination therapy with FK 506 and 15-deoxyspergualin in pancreatic islet xenografting. 1992 Transplant. Proc. pmid:1376513
Ogasa N et al. Successful transplantation of newborn rat intestine as a free graft. 1992 Transplant. Proc. pmid:1376514
Graeb C et al. Cytoimmunologic monitoring of small bowel allograft recipients. 1992 Transplant. Proc. pmid:1376515
Date K et al. Effect of FK 506 on graft survival in rat small intestinal allografts. 1992 Transplant. Proc. pmid:1376516
Hatazawa C et al. Effect of FK 506 on bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376517
Jain A et al. Intravenous, oral pharmacokinetics, and oral dosing of FK 506 in small bowel transplant patients. 1992 Transplant. Proc. pmid:1376518
Masutani H et al. Suppression of the histologic changes of GVHD by FK 506 in rat small bowel transplantation. 1992 Transplant. Proc. pmid:1376519
Santiago SF et al. Effect of short-term immunosuppressive therapy with FK 506 or CyA on the donor in small intestine allotransplantation in rats. 1992 Transplant. Proc. pmid:1376520
Utsunomiya H et al. Effect of FK 506 on orthotopic small bowel transplantation in rats. 1992 Transplant. Proc. pmid:1376521
Yagihashi A et al. Changes in cell surface markers in human small bowel transplantation with FK 506. 1992 Transplant. Proc. pmid:1376522
Abu-Elmagd K et al. Management of intestinal transplantation in humans. 1992 Transplant. Proc. pmid:1376523
Takaori K et al. Basic study on immunologic effects of cyclosporine and FK 506 for application to pancreatic transplantation. 1992 Transplant. Proc. pmid:1376531
Foor F et al. Calcineurin mediates inhibition by FK506 and cyclosporin of recovery from alpha-factor arrest in yeast. 1992 Nature pmid:1281518
Goldfeld AE et al. Transcription of the tumor necrosis factor alpha gene is rapidly induced by anti-immunoglobulin and blocked by cyclosporin A and FK506 in human B cells. 1992 Proc. Natl. Acad. Sci. U.S.A. pmid:1281550
Morikawa K et al. The distinct effects of FK506 on the activation, proliferation, and differentiation of human B lymphocytes. 1992 Transplantation pmid:1281561
Moutabarrik A et al. FK506-induced kidney tubular cell injury. 1992 Transplantation pmid:1281562
Yagihashi A et al. HLA matching effect in liver transplantation. 1992 Transplant. Proc. pmid:1281569
Kobayashi M et al. Posttransplant donor-specific T-lymphocytotoxic antibody in liver transplant patients with a positive crossmatch. 1992 Transplant. Proc. pmid:1281570
Lemster B et al. Cytokine gene expression in murine lymphocytes activated in the presence of FK 506, bredinin, mycophenolic acid, or brequinar sodium. 1992 Transplant. Proc. pmid:1281576
Tze WJ et al. FK 506: an effective immunosuppressant for islet xenotransplantation. 1992 Transplant. Proc. pmid:1281577
Kamei T et al. Established intraportal islet allograft is rejected despite the acceptance of donor-specific second cardiac allograft. 1992 Transplant. Proc. pmid:1281579
Woo J et al. FK 506 treatment following syngeneic bone marrow transplantation does not inhibit clonal deletion of V beta 5+ or V beta 11+ T cells. 1992 Transplant. Proc. pmid:1281583
Souza ER et al. Acute effects of FK 506 on glomerular hemodynamics. 1992 Transplant. Proc. pmid:1281585
Hanke JH et al. FK506 and rapamycin selectively enhance degradation of IL-2 and GM-CSF mRNA. 1992 Lymphokine Cytokine Res. pmid:1281674
Logan TM et al. Side chain and backbone assignments in isotopically labeled proteins from two heteronuclear triple resonance experiments. 1992 FEBS Lett. pmid:1281793
Kenmochi T et al. [The effect of FK506 on segmental pancreas allograft in mongrel dogs]. 1992 Nihon Geka Gakkai Zasshi pmid:1378526
Mouzaki A et al. Cyclosporin A and FK506 prevent the derepression of the IL-2 gene in mitogen-induced primary T lymphocytes. 1992 Cytokine pmid:1378764
Ramamoorthy S et al. Selective impairment of taurine transport by cyclosporin A in a human placental cell line. 1992 Pediatr. Res. pmid:1378960
Armitage JM et al. Clinical trial of FK 506 immunosuppression in adult cardiac transplantation. 1992 Ann. Thorac. Surg. pmid:1379032
Thomson AW The spectrum of action of new immunosuppressive drugs. 1992 Clin. Exp. Immunol. pmid:1379130
Fischer G et al. Mip protein of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (PPlase) activity. 1992 Mol. Microbiol. pmid:1379319
Rondeau E [Mechanism of action of the new immunosuppressants: cyclosporin A, FK 506 and rapamycin]. 1992 Nephrologie pmid:1379348
Schreiber SL Immunophilin-sensitive protein phosphatase action in cell signaling pathways. 1992 Cell pmid:1379518
Aldape RA et al. Charged surface residues of FKBP12 participate in formation of the FKBP12-FK506-calcineurin complex. 1992 J. Biol. Chem. pmid:1379588
Langrehr JM et al. Nitric oxide production in host-versus-graft and graft-versus-host reactions in the rat. 1992 J. Clin. Invest. pmid:1379617
Kumano K et al. [Functional and morphological changes in rat kidney induced by FK506 and its reversal by various vasodilators]. 1992 Nippon Hinyokika Gakkai Zasshi pmid:1379657
Woodle ES et al. FK506: inhibition of humoral mechanisms of hepatic allograft rejection. 1992 Transplantation pmid:1379749
First MR Renal transplantation for the nephrologist: new immunosuppressive drugs. 1992 Am. J. Kidney Dis. pmid:1371201
Granelli-Piperno A SRC-related proto-oncogenes and transcription factors in primary human T cells: modulation by cyclosporin A and FK506. 1992 J. Autoimmun. pmid:1380242
Reem GH Molecular mode of action of cyclosporin and FK506 in human thymocytes. 1992 J. Autoimmun. pmid:1380243
Bach JF Immunointervention in autoimmune diseases from cellular selectivity to autoantigen specificity. 1992 J. Autoimmun. pmid:1380245
Baumann G et al. Molecular mechanisms of immunosuppression. 1992 J. Autoimmun. pmid:1380246
Walpoth B et al. Assessment of new immunosuppressive drugs in a rat cardiac allograft heterotopic model. 1992 Eur Surg Res pmid:1380460
Petros AM et al. Conformation of two non-immunosuppressive FK506 analogs when bound to FKBP by isotope-filtered NMR. 1992 FEBS Lett. pmid:1380470
Van Thiel DH et al. FK 506 reduces the injury experienced following renal ischemia and reperfusion. 1992 Ren Fail pmid:1380720
Bolton C The efficacy of cyclosporin A, FK-506 and prednisolone to modify the adoptive transfer of experimental allergic encephalomyelitis (EAE). 1992 Agents Actions pmid:1380765
Terada N et al. Rapamycin inhibits the phosphorylation of p70 S6 kinase in IL-2 and mitogen-activated human T cells. 1992 Biochem. Biophys. Res. Commun. pmid:1380801
Friccius H et al. The effects of the antifungal azoles itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells. 1992 Int. J. Immunopharmacol. pmid:1380951
Dumont FJ et al. The immunosuppressive and toxic effects of FK-506 are mechanistically related: pharmacology of a novel antagonist of FK-506 and rapamycin. 1992 J. Exp. Med. pmid:1380976
Langrehr JM et al. Evidence that indefinite survival of small bowel allografts achieved by a brief course of cyclosporine or FK506 is not due to systemic hyporesponsiveness. 1992 Transplantation pmid:1384185
McCarthy SA et al. The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes. 1992 Transplantation pmid:1384186
Dhar DK et al. The salutary effect of FK506 in ischemia-reperfusion injury of the canine liver. 1992 Transplantation pmid:1384188
Ericzon BG et al. FK506-induced impairment of glucose metabolism in the primate--studies in pancreatic transplant recipients and in nontransplanted animals. 1992 Transplantation pmid:1384189
Meiser BM et al. Continuous infusion of angiopeptin significantly reduces accelerated graft vessel disease induced by FK 506 in a rat heart allograft model. 1992 Transplant. Proc. pmid:1384201
Wakabayashi H et al. Effect of FK 506 and cyclosporine A on hepatic energy status in the rat after warm ischemia, as monitored by 31P nuclear magnetic resonance spectroscopy in vivo. 1992 Transplant. Proc. pmid:1384205
Griffin AD et al. FK 506 in canine renal transplantation. 1992 Transplant. Proc. pmid:1384209
Griffiths RJ et al. Characterisation of passively transferred antigen arthritis induced by methylated bovine serum albumin in the rat: effect of FK 506 on arthritis development. 1992 Agents Actions pmid:1384284
Todo S et al. Intestinal transplantation in composite visceral grafts or alone. 1992 Ann. Surg. pmid:1384443
Massol N et al. Rabbit FKBP59-heat shock protein binding immunophillin (HBI) is a calmodulin binding protein. 1992 Biochem. Biophys. Res. Commun. pmid:1384470
Siekierka JJ and Sigal NH FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. 1992 Curr. Opin. Immunol. pmid:1384551
Hultsch T et al. The effect of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. 1992 Mol. Biol. Cell pmid:1384815
Petros AM et al. Identification of solvent-exposed regions of an FK-506 analog, ascomycin, bound to FKBP using a paramagnetic probe. 1992 J. Biomol. NMR pmid:1384850